Barclays’s Lantern Pharma LTRN Stock Holding History

Barclays’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25	Buy	+6	New	+$18	﹤0.01%	5279

Other funds holding LTRN

EAM

Empery Asset Management New York $86.5M AUM

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Barclays's LTRN Position: Q2 2026 in Review

Barclays opened a new position in Lantern Pharma (LTRN) in Q2 2026: 6 shares worth $25. The stake represents ﹤0.01% of the portfolio and ranks #5279 among its holdings.

39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

Barclays held 6 shares of Lantern Pharma worth $25 as of Q2 2026.
Lantern Pharma was a new Barclays position in Q2 2026.
Lantern Pharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5279 holding.
39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.